Abstract Library

#4318 Management of asymptomatic, sporadic, small non-functional pancreatic neuroendocrine tumours: Active surveillance or surgery? A retrospective cohort study in the SEER database

Introduction: Non-functional pancreatic neuroendocrine tumours (NF-PanNETs) exhibit a wide heterogeneity of aggressiveness and optimal management of asymptomatic, sporadic, small PanNETs remains controversial.

Conference:

Presenting Author: Chen C

Authors: Chen C, Zheng Z, Li P, Hu H,

Keywords: Pancreatic neuroendocrine tumour, surveillance, surgery, prognosis, SEER,

#4185 Primary hepatic neuroendocrine neoplasms – Clinical characteristics and treatment outcomes of a rare disease

Introduction: Liver involvement in Neuroendocrine Neoplasms (NEN) most commonly encompasses metastases from other organs or from an unknown primary. The current WHO classification defines primary hepatic NEN (PHNEN) as a distinct entity. With only few cases of PHNEN reported and difficulty to discern them from hepatic metastases, evidence on optimal management is very limited.

Conference:

Presenting Author:

Authors: Apostolidis L, Kender Z, Flegka V, Winkler E, Krug S,

Keywords: hepatic NEN, liver NEN, PHNEN,

#3887 Characteristics and management of high grade gastroenteropancreatic neuroendocrine neoplasms – A Belgian retrospective analysis from the DNET & NETwerk registry

Introduction: High grade gastroenteropancreatic neuroendocrine neoplasms (HG-GEPNEN) comprise neuroendocrine carcinoma (NEC) and well-differentiated neuroendocrine tumors (NETG3). These entities exhibit many differences in behaviour, prognosis and sensitivity to chemotherapy. Data about their optimal management are still scarce.

Conference:

Presenting Author:

Authors: Islam O, Sarti K, Verslype C, van Laethem J, Kalantari Hassan R,

Keywords: Neuroendocrine tumor, high-grade gastroenteropancreatic NEN (HG GEPNEN), neuroendocrine carcinoma, neuroendocrine tumor g3, retrospective data, clinical data, pathology,

#3657 Prognostic and therapeutic role of a novel genomic subtyping of target gene sequencing on gastroenteropancreatic neuroendocrine carcinoma

Introduction: Despite of emerging genomic discoveries, no optimal management for gastroenteropancreatic neuroendocrine carcinoma (GEPNEC) were found.

Conference:

Presenting Author:

Authors: Zhang J, Li J, Lu M, Sun Y, Shen L,

Keywords: Gastroenteropancreatic Neuroendocrine carcinoma, Target gene sequencing, Genomic subtyping, Efficacy, Prognosis, Second-line treatment,

#3629 Evaluating the systemic management options in advanced pulmonary carcinoid tumors – A systematic review

Introduction: Pulmonary carcinoids have been classically described as indolent, with treatment options largely focusing on surgical resection. However, with increasing prevalence and growing awareness, cases of advanced pulmonary carcinoids, have been reported. Due to the paucity of clinical trials, there is a lack of evidence-based systemic treatments, contributing to significant variation between guidelines and global recommendations. Ultimately, this leads to suboptimal management of patients with advanced disease.

Conference:

Presenting Author:

Authors: Shah H, Shah M,

Keywords: Pulmonary Carcinoid, Systemic therapy,